Clindamycin

Generic Name: Clindamycin

Brand Names: Acanya, Benzaclin, Biacna, Cabtreo, Cleocin, Cleocin-T, Clindacin, Clindagel, Clindesse, Clindoxyl, Dalacin, Dalacin C, Duac, Evoclin, Neuac, Onexton, Veltin, Xaciato, Ziana

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₃₃ClN_₂O_₅S

CAS Number: 18323-44-9

Unique Ingredient Identifier: 3U02EL437C

Background: Clindamycin is a semi-synthetic lincosamide antibiotic used in the treatment of a variety of serious infections due to susceptible microorganisms as well as topically for acne vulgaris. It has a relatively narrow spectrum of activity that includes anaerobic bacteria as well as gram-positive cocci and bacilli and gram-negative bacilli. Interestingly, clindamy...

Indication: In oral and parenteral formulations, clindamycin is indicated for the treatment of serious infections caused by susceptible anaerobic bacteria, as well as susceptible staphylococci, streptococci, and pneumococci. Used topically, it is indicated for the treatment of acne vulgaris and is available in combination with benzoyl peroxide or tretinoin for this purp...

Associated Conditions: Abscess, Intra-Abdominal caused by Anaerobic Bacterial Infection, Acne Vulgaris, Babesiosis, Bacterial Endocarditis, Bacterial Vaginosis (BV), Bloodstream Infections caused by Anaerobic Bacterial Infection, Bone and Joint Infections caused by susceptible Staphylococcus, Empyema caused by Anaerobic Bacterial Infection, Endometritis caused by Anaerobic Bacterial Infection, Lung Abscess caused by Anaerobic Bacterial Infection, Malaria caused by Plasmodium falciparum, Mixed Vaginal Infections, Pelvic cellulitis caused by Anaerobic Bacterial Infection, Peritonitis caused by Anaerobic Bacterial Infection, Pneumocystis Jirovecii Pneumonia, Pneumonitis caused by Anaerobic Bacterial Infection, Respiratory Tract Infections (RTI) caused by susceptible Staphylococcus, Respiratory Tract Infections (RTI) caused by susceptible pneumococci, Respiratory Tract Infections (RTI) caused by susceptible streptococci, Septicemia caused by susceptible Staphylococcus, Septicemia caused by susceptible streptococci, Skin Structures and Soft Tissue Infections caused by Anaerobic Bacterial Infection, Skin Structures and Soft Tissue Infections caused by susceptible Staphylococcus, Skin Structures and Soft Tissue Infections caused by susceptible streptococci, Toxoplasmosis, Tubo-ovarian abscess caused by Anaerobic Bacterial Infection, Vaginal Candidiasis, Vaginal Mycosis, Chronic Bone and Joint Infections caused by Susceptible infections, Moderate Acne vulgaris, Post-surgical vaginal cuff infection caused by Anaerobic Bacterial Infection, Viridans group streptococci

Associated Therapies: -

Clinical Trials

Antibiotics Usage in Pediatric Orthopaedic Percutaneous Surgery (APOPS)

Phase 4

Completed

Conditions: Supracondylar Humerus Fracture
Post Operative Wound Infection

Interventions: Drug: Saline
Drug: Cefazolin
Drug: Clindamycin

First Posted Date: 2017-08-25

Last Posted Date: 2024-08-09

Lead Sponsor: Sumit Gupta

Target Recruit Count: 160

Registration Number: NCT03261830

Locations: 🇺🇸
University of Missouri Health System, Columbia, Missouri, United States

S. Aureus Decolonization in HPN Patients.

Not Applicable

Terminated

Conditions: Motility Disorder
Staphylococcus Aureus

Interventions: Drug: Doxycycline
Drug: Trimethoprim
Drug: Sulfamethoxazole/trimethoprim
Drug: Clindamycin
Drug: Clarithromycin
Drug: Ciprofloxacin
Drug: Fusidic Acid
Drug: Rifampin
Drug: Chlorhexidine
Drug: Mupirocin
Drug: Betadine

First Posted Date: 2017-06-01

Last Posted Date: 2022-05-31

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 63

Registration Number: NCT03173053

Locations: 🇩🇰
Rigshospitalet, Copenhagen, Denmark
🇩🇰
Aalborg Universitetshospital, Aalborg, Denmark
🇳🇱
Radboud UMC, Nijmegen, Gelderland, Netherlands

and more 1 locations

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

Phase 3

Completed

Conditions: Bacterial Infections
Methicillin-Resistant Staphylococcus Aureus
Staphylococcal Skin Infections

Interventions: Drug: Dalbavancin
Drug: Vancomycin
Drug: Oxacillin
Drug: Flucloxacillin
Drug: Cefadroxil
Drug: Clindamycin

First Posted Date: 2016-06-28

Last Posted Date: 2024-01-17

Lead Sponsor: AbbVie

Target Recruit Count: 199

Registration Number: NCT02814916

Locations: 🇱🇹
Klaipeda Children's Hospital /ID# 235652, Klaipeda, Lithuania
🇧🇬
University Multiprofile Hospital for Active Treatment Deva Maria EOOD Burgas /ID# 235965, Bulgas, Bulgaria
🇧🇬
MHAT (Multiprofile Hospital for Active Treatment) /ID# 235539, Kozloduy, Bulgaria

and more 81 locations

Interventional Bioremediation of Microbiota in Metabolic Syndrome

Phase 2

Terminated

Conditions: Pre-Diabetes

Interventions: Other: Placebo
Drug: Vancomycin
Drug: Neomycin
Drug: Clindamycin
Procedure: Fecal Microbiota Transplantation

First Posted Date: 2016-04-07

Last Posted Date: 2023-02-22

Lead Sponsor: University of Minnesota

Target Recruit Count: 12

Registration Number: NCT02730962

Locations: 🇺🇸
University of Minnesota Medical Center, Minneapolis, Minnesota, United States

Aspiration Treatment of Perianal Abscess

Not Applicable

Completed

Conditions: Anal Fistulas

Interventions: Device: MEDIPLAST® (aspiration)
Procedure: incision
Drug: Clindamycin

First Posted Date: 2015-10-23

Last Posted Date: 2020-11-13

Lead Sponsor: University of Southern Denmark

Target Recruit Count: 111

Registration Number: NCT02585141

Locations: 🇩🇰
Odense University Hospital, Odense, Denmark

Trial of Randomized Antibiotic Administration in Percutaneous Nephrolithotomy

Phase 3

Completed

Conditions: Kidney Stones

Interventions: Drug: cephalosporins
Drug: Fluoroquinolones
Drug: Clindamycin
Drug: Ampicillin/Gentamicin

First Posted Date: 2015-10-19

Last Posted Date: 2023-09-06

Lead Sponsor: Northwell Health

Target Recruit Count: 98

Registration Number: NCT02579161

Locations: 🇺🇸
North Shore University Hospital, Manhasset, New York, United States
🇺🇸
Long Island Jewish Medical Center, New Hyde Park, New York, United States

PK of Clindamycin and Trimethoprim-sulfamethoxazole in Infants and Children

Phase 1

Completed

Conditions: Bacterial Infections

Interventions: Drug: trimethoprim-sulfamethoxazole
Drug: Clindamycin

First Posted Date: 2015-06-19

Last Posted Date: 2020-09-21

Lead Sponsor: Michael Cohen-Wolkowiez

Target Recruit Count: 51

Registration Number: NCT02475876

Locations: 🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸
University of Michigan C.S. Mott Children's Hospital, Ann Arbor, Michigan, United States